# Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)

> **NCT04170556** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fundacion Clinic per a la Recerca Biomédica** · enrollment: 69 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04170556
- **Lead sponsor:** Fundacion Clinic per a la Recerca Biomédica
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-16
- **Primary completion:** 2024-07-09
- **Final completion:** 2024-07-09
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-09-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170556, "Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04170556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*